Back to results
US 10,851,099 B2Granted
Dipeptide piperidine derivatives
AssigneeOncoArendi Therapeutics S.A.
InventorsRoman Blaszczyk, Anna Gzik, Bartlomiej Borek, Marek Dziegielewski, Karol Jedrzejczak, Julita Nowicka, Jacek Chrzanowski, Joanna Brzezinska, Adam Golebiowski, Jacek Olczak, Marcin Mikolaj Grzybowski, Jolanta Peczkowicz-Szyszka
Life of this patent
Estimating the term…
Abstract
The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.
Claims22
A compound of the Formula (I):
- wherein:
- R1 is selected from the group consisting of H, straight-chain or branched (C1-C6)alkyl, HC(O)—, and (C1-C6)alkyl-C(O)—;
- R2 and R3 are each independently selected from hydrogen, straight-chain or branched (C1-C6)alkyl or (C1-C6)alkyl-C(O)—,
- or R2 and R3 taken together with the boron atom and oxygen atoms to which they are bound form a 4-, 5-, 6- or 7-membered ring that is fully saturated, or partially saturated,
- or R2 and R3 taken together with the boron atom and oxygen atoms to which they are bound form a diester of the boronic acid and polyalcohols selected from:
- pinanediol, mannitol, glycerol, xylitol, sorbitol, or erythritol,
- or R2 and R3 taken together with the boron atom and oxygen atoms to which they are bound form an anhydride or mixed ester-anhydride of the boronic acid and hydroxy acids or di-carboxylic acids selected from:
- iminodiacetic acid or N-methyliminodiacetic acid or oxalic acid or tartaric acid or citric acid or malic acid or malonic acid or mandelic acid or glycolic acid or lactic acid or 3-hydroxypropionic acid;
- R4 is selected from the group consisting of H, straight-chain and branched (C1-C6)alkyl;
- R5 is selected from the group consisting of H, F, methyl, ethyl, propyl, isopropyl, —CH2NH2, —CH2NHCH3, —CH2NHCH2CH3, —CH2NHCH(CH3)2, —CH2N(CH3)2, —CH2N(CH3)CH2CH3, —CH2N(CH2CH3)2, —CH2N(CH3)CH(CH3)2, —CH2-azetidinyl, —CH2-pyrrolidinyl, and —CH2-piperidinyl;
- R6 is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva;
- and
- R7 and R8 are each independently selected from hydrogen and methyl,
- or, when R7 is H, R6 and R8 together with the nitrogen atom carrying R8 form a pyrrolidine ring (proline side chain);
- or a pharmaceutically acceptable salt thereof.
12 more elements
A process for preparing a compound of Formula Ib:
- or a precursor thereof, wherein:
- R6 is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp;
- 1-Me-Trp and Nva;
- or a pharmaceutically acceptable salt thereof;
- comprising:
- (a) reducing an ester of the formula
- where
- Pg is methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C1-C6 alkoxy, or C1-C6 alkyl;
- RE is C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl(C1-C6)alkyl, or methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C1-C6 alkoxy, or C1-C6 alkyl to yield a protected hydroxymethylpyrrolidine of the formula:
- (b) subjecting the protected hydroxymethylpyrrolidine to ring expansion conditions to produce a protected piperidine of the formula:
- (c) oxidizing the protected piperidine to form an enantiomerically enriched product comprising a ketone of the formula:
- (d) reacting the ketone with cyanide and an amine source to yield an α-cyanoamine of the formula:
- (e) acylating the amino group of the α-cyanoamine to produce an acylated α-cyanoamine of the formula:
- wherein RN is C2-C6 alkanoyl.
11 more elements
Dependencies are inferred from the claim text.